NeuroInsights and BioToday Launch Neurotechnology Investment Newsletter in Japan; Neurotech Insights Helps Japanese Investors and Companies Profit from Advances in the Brain Industry

SAN FRANCISCO--(BUSINESS WIRE)--Nov. 1, 2005--NeuroInsights and BioToday announced today the launch of Neurotech Insights, the neurotechnology investment newsletter, in Japanese. Neurotechnology is a highly active and profitable industry, including pharmaceuticals, devices and diagnostics for brain-related illness, with global revenues of almost $100 billion in 2004.

Neurotech Insights provides in-depth feature articles, private company news, product development tracking, executive interviews, and public stock commentary based on an intimate understanding of the industry's players and products. This month's issue is focused on the obesity market and includes an interview with Arena Pharmaceutical's CEO, Jack Lief. Previous issues have discussed stem cells, stroke, pain, and schizophrenia. Future issues will discuss Alzheimer's disease, epilepsy, and depression.

“Neurotech Insights will improve global visibility among Japan's neurotech business and scientific leaders strengthening their worldwide competitiveness.”

"NeuroInsights is pleased to be working with BioToday to translate and distribute Neurotech Insights, the neurotechnology industry's leading global investment newsletter to Japanese executives and investors," said Zack Lynch, publisher of Neurotech Insights.

"Neurotech Insights is the world's first investment newsletter to provide comprehensive information across CNS diseases, products and market opportunities, that is unprecedented in commercially available reports," said Seimiya Masato, President of BioToday. "Neurotech Insights will improve global visibility among Japan's neurotech business and scientific leaders strengthening their worldwide competitiveness."

About NeuroInsights

As the neurotechnology market authority, NeuroInsights(TM) helps investors, industry executives and the public understand and profit from the rapid growth of companies treating brain and nervous system-related illnesses, providing publications, advisory services and 3rd party research.

NeuroInsights' Neurotech Index, an equal-dollar weighted tracking index of 30 neurotechnology companies, is up 31% over a one year period, compared to a 7% gain in both the S&P 500 Index and the NASDAQ Composite. Information about the index is featured each month in Neurotech Insights.

For more information visit www.neuroinsights.com.

About BioToday

BioToday is the leading provider of web-based resources and information to the Japanese life science industry. Since 2001, BioToday has helped to accelerate communication and discovery among business and scientific leaders in the Japanese biopharmaceutical market. BioToday.com offers an unparalleled distribution channel for global biopharmaceutical and research news in Japanese. For more information, visit www.biotoday.com.

Availability

Neurotech Insights is available in English from NeuroInsights at www.neurotechinsights.com and in Japanese from BioToday at http://neurotech.biotoday.com/.